Exploring How DNA Damage And Mutations Lead To The Uncontrolled Growth Of Cancer Cells?

Yashvi Chhabra

DOI: 10.29322/IJSRP.15.09.2025.p16506
https://dx.doi.org/10.29322/IJSRP.15.09.2025.p16506

Paper Received Date: 18th July 2025
Paper Acceptance Date: 28th August 2025
Paper Publication Date: 6th September 2025

ABSTRACT

In the initiation and development of cancer, DNA damage plays a very crucial role. In the case of environmental perturbation, mutation events in critical control genes may occur as the integrity of genetic material is lost, either due to replication errors, oxidative stress, etc. And provided that these are proto-oncogenes or tumour suppressor genes, they can interfere with normal control of the cell cycle, programmed cell death (apoptosis) and repair of damaged DNA(Branzei & Foiani, 2023). Consequently, they can start to multiply out of control, which can result in the appearance of growth and malignancy. This abstract discusses the molecular processes that connect the occurrences of DNA damage and mutations with the out-of-control growth of cancer cells, pointing to their importance in the development of cancers.

Keywords: *DNA damage, genetic mutations, cancer development, tumour suppressor genes, proto-oncogenes, cell cycle regulation, apoptosis, uncontrolled cell growth, genomic instability, carcinogenesis.*

1. INTRODUCTION

Cancer is an illness which involves unrestricted cell division and the development of abnormal cells. Genetic mutations or changes, especially in the form of DNA damage and mutations, lie at the heart of this transformation because they interfere with the normal cellular functions(Bryant et al., 2023). The body uses repair mechanisms to correct errors in the DNA, but in a normal scenario, this has to be fixed; but in the event that the repair mechanisms fail, then the error may accumulate or lead to a mutation. The altered genes are usually those that govern the cell cycle, apoptosis, and DNA repair, making them unchecked. The knowledge of how DNA damage and mutations work in cancer, and their early detection and treatment, is critical. The paper discusses the molecular basis of these processes in oncogenesis.

1.1 BACKGROUND OF THE STUDY

Cancer development is strongly related to the accumulation of genetic changes, which in most cases are caused by DNA alterations. DNA may be damaged by several internal agents, such as reactive oxygen species, replication errors, or external ones such as ultraviolet radiation and carcinogenic chemicals(Klaunig, 2022). Despite the elaborate cellular repair processes that cells have developed, there can be damaged sites that may be hard to repair, resulting in permanent mutation. Such mutations, particularly in genes which regulate the growth/division/death of cells, can facilitate the change of normal cells into cancerous cells. Getting to know more about the causes and effects of damage to DNA is essential in comprehending the biology of cancer in hopes of enhancing prevention and disease management tactics.

1.2 RESEARCH GAP

Although much has been learnt regarding the genetic causes behind cancer, there is still a major gap in associating certain kinds of DNA damage with certain kinds of mutation patterns and cancer types(Yadav, Couch, & Nathanson, 2023). Although numerous studies have revealed the major oncogenes and tumour suppressor genes that are affected by mutation, the exact sequence of molecular events used to alter normal DNA into a cancerous state is not perfectly known. Also, the personal response to DNA repair and the extent of environmental exposure make it difficult to predict cancer risk. Further studies are required in the mapping of DNA damage responses in a wide range of cells, as well as he creation of early-detection tools on pre-malignant occurrences in genetic changes before the occurrence of the tumour.

1.3 RESEARCH OBJECTIVES

1. To identify the primary sources of DNA damage contributing to genetic mutations in human cells.
2. To examine how mutations in oncogenes, tumour suppressor genes, and DNA repair genes lead to uncontrolled cell growth.
3. To analyse the role of DNA repair mechanisms in preventing or allowing the accumulation of mutations leading to cancer.
4. To evaluate recent findings on the molecular pathways linking DNA damage to specific cancer types and explore their implications for early diagnosis and targeted therapy.

1.4 RESEARCH QUESTIONS

1. Which are the key endogenous and exogenous causes of DNA damage, and those that are related to the initiation of cancer?
2. What is the effect of mutation in important genes like oncogenes, tumour suppressor genes, DNA repair genes and growth of uncontrolled cells?
3. How significant is the role of DNA repair mechanisms in the genomic stability maintenance and inhibition of malignant transformation?
4. What role can the understanding of DNA damage-related mechanisms play in enhancing early detection of cancer and the development of specific treatment steps?

1.5 LIMITATIONS OF THE STUDY

A limitation to this study is that the development of cancer is complex and variable, hence hard to generalise of results to other types of cancer. The pathways of action of molecular DNA damage to abnormal cell growth tend to differ depending on the particular kinds of tissues, genetic predisposition, and environmental factors. There is also a great deal of the current insight based on either in vitro or animal-model-based research, which is not necessarily human in all respects. The usefulness of biomarkers and diagnostic tools is also limited, which can inhibit accurate tracing of the mutation pathways at the initial stages of cancer. These issues indicate the lack of additional studies carried out via the human-specific framework and longitudinal clinical trials.

1.6 RATIONALE OF THE STUDY

This study is justified by the reason that damage to DNA and mutation due to such damage causes the aspect of normal cells to transform into cancerous cells. Investigating the molecular process at work, including interference with the tumour suppressor genes and the activation of the oncogenes, the research also attempts to show how cancer is initiated. This information is vital in the development of specific treatment methods and enhancement of early detection protocols and aspects of personalised medicine in cancer management.

2. LITERATURE REVIEWS

2.1 THE ROLE OF ENVIRONMENTAL AND ENDOGENOUS FACTORS IN DNA DAMAGE

According to **Klaunig (2022)**, oxidative stress is remarkably at the centre of initiating and promoting cancer. The paper indicates that reactive oxygen species (ROS) produced during our normal metabolism or as a result of exposure to environmental toxins are able to cause severe damage to DNA by means of base alteration, strand breakage and cross-linking. The cells undergo oxidative stress and exhibit genomic instability when ROS production overwhelms the antioxidant defence system and repair activities. The author claims that sustained oxidative injury is a key contributor to mutagenesis and the disturbance of cellular pathways involved in regulating cell growth and cell death, both of which eventually lead to cancer.

Tudek et al. (2021) study the two-faced aspect of the consequences of oxidative damage to DNA and its repair, by examining both its role in ageing and cancer development. The authors provide evidence that the unusual oxidant products, including 8-oxoguanine, are common and mutagenic unless they are repaired effectively. They emphasise the role of the base excision repair (BER) as a protective stratification against such damage. The paper, however, also records the fact that defective or overburdened repair systems may lead to mutation augmentation and genomic instability, absolutely, in developing tissues. Tudek et al. highlight the fact that the alterations in chronic oxidative DNA damage and its impaired repair are leading to carcinogenesis and age-related diseases.

2.2 GENETIC SUSCEPTIBILITY AND HEREDITARY CANCER SYNDROME

In case you do not know much about Constitutional Mismatch Repair-Deficiency (CMMRD) syndrome, a now-rare but historically severe hereditary cancer syndrome of mismatched repair, **Wimmer and Kratz (2021**) have offered an editorial review of its pathology. It is described in the paper that patients with CMMRD tend to develop multiple malignancies as children; such malignancies may be haematological, brain, and gastrointestinal malignancies. Wimmer and Kratz underline the difficulties of the diagnosis because of the similarity of clinical manifestations of the condition to those of other disorders and indicate the significance of the genetic screening of a child early enough. The study further presents a case of complete surveillance measures and genetic counselling to the concerned family of affected people to cope with the risk of cancer.

The article by 3 authors (**Yadav, Couch, and Nathanson, 2023)** talks about the developing situation of germline genetic testing in the identification of subjects that are at high risk of developing hereditary cancer syndromes. They target such genes as BRCA1, BRCA2, TP53, and PALB2 that cause dramatic increases in the risk of cancer, given that they have been mutated. The authors emphasise the achievements in the areas of next-generation sequencing technologies, making testing more available and extensive. They also deal with issues like interpreting uncertain significant variants and unequal access to genetic services. Yadav et al. encourage the use of genetic testing in clinical practice to support the development of personalised prevention, early detection and treatment approaches of affected/at-risk groups.

2.3 MUTATIONAL LANDSCAPES OF COMMON CANCERS

The team of **Berger et al. (2022)** performed wide-scale high-throughput screening in which they identified the key genes that are vital to the survival of different cancer cell lines. They have performed CRISPR-Cas9 screening of a large collection of tumour types, identifying gene dependencies that are unique to individual cancers. Their results indicate that cancer cells have a set of different genes from normal cells, providing a potential target for medical therapy. The context-dependency of gene essentiality has also been emphasised in this paper, and it is likely that in the future, precision treatments based on identifying individual vulnerabilities in cancer can be developed that can improve the precision of oncological therapies.

Martincorena and Campbell (2023) gave a detailed concern regarding somatic mutations across normal and cancerous human cells. As they pointed out in their studies, it is known that somatic mutations naturally build up with age in all healthy tissues, although only some of them, especially the ones that target important regulatory genes, promote cancer. They distinguished between driver mutations that play a role in tumorigenesis and passenger mutations that never have any functional effect. Such a difference is critical when it comes to cancer diagnostics and treatment approaches. In their work, valuable information is given on the relationship between observing a particular mutation pattern with early diagnosis and the creation of targeted anti-cancer drugs against a particular type of cancer.

3. RESEARCH METHODOLOGY

The current study uses a descriptive research approach, which is a qualitative research methodology to understand the role of DNA damage and mutation in the uncontrollable proliferation of cancer cells as observed with a comprehensive literature review(Tudek et al., 2021). The first objective is the synthesis of previously acquired scientific knowledge on molecular mechanisms, genetic predisposition, as well as processes of mutation occurring during interventional oncogenesis. The approach will be appropriate in a theoretical study of the biological mechanisms and the functionality of genes without necessarily performing experiments in the laboratory.

The study relies on the extracts of peer-reviewed journal articles, scientific databases (PubMed, ScienceDirect, Nature, Springer), reports of institutions, and recent genomic studies (The Cancer Genome Atlas, TCGA). It was based on articles covered during the timeframe of 2015-2024, with the selection criteria being articles on studies performed about endogenous and exogenous DNA damage, the genetics of cancer, hereditary cancer syndromes, and repairing pathways in DNA. Relevant literature was retrieved using keywords like DNA damage, mutations in cancer, oncogenes, tumour suppressor genes, genomic instability and hereditary cancer syndromes.

The literature obtained was broken down into themes. All articles were evaluated regarding their contribution to the knowledge of factors causing, types and consequences of DNA damages in cancer development(Vogelstein et al., 2022). Key themes under which the data were organised included sources of DNA damage, genetic mutations, failure of DNA repair, as well as the implications of hereditary syndromes. Such thematic arrangement allowed organised comparison of various types and mechanisms of cancer in several studies.

A critical analysis approach was used to evaluate the validity, strengths, and limitations of the reviewed literature. The paper includes both seminal studies and recent research findings to provide a balanced view of foundational knowledge and emerging discoveries. The study also incorporates data from recent genetic and molecular oncology reviews to highlight current developments and gaps in the field.

While this methodology does not involve experimental procedures or statistical analysis, it ensures academic rigour by relying exclusively on high-quality, peer-reviewed sources(Jackson & Bartek, 2021). The qualitative synthesis aims to provide an in-depth understanding of how accumulated DNA damage and mutations disrupt cellular regulation, contributing to cancer progression. The findings serve as a basis for further experimental research and potential clinical applications, particularly in early detection and targeted therapies.

4. DATA ANALYSIS



The column bar graph illustrates the estimated contributions of six major sources of DNA damage that lead to genetic mutations in human cells(Lord & Ashworth, 2022). These sources are critical in understanding the onset and progression of cancer, as they disrupt the genetic material essential for normal cell functioning.

The graph highlights Reactive Oxygen Species (ROS) as the leading contributor, accounting for 25% of DNA damage. ROS are by-products of normal cellular metabolism and oxidative stress, and their continuous generation within cells makes them a prominent internal threat. When not neutralised by antioxidants, ROS can cause mutations by attacking DNA bases and inducing strand breaks.

UV radiation follows with a 20% contribution. It is an external factor that primarily affects skin cells, leading to the formation of pyrimidine dimers and other photoproducts that distort the DNA structure. Prolonged exposure to sunlight significantly increases mutation risk, particularly for skin cancers.

Tobacco smoke is responsible for 18% of DNA damage. It contains numerous carcinogens such as polycyclic aromatic hydrocarbons and nitrosamines, which form bulky DNA adducts and directly alter base-pairing during replication. Ionizing radiation, including X-rays and gamma rays, contributes 15%. It causes double-strand breaks, a particularly hazardous form of DNA damage that is challenging to repair accurately.

Replication errors, though part of normal DNA synthesis, account for 12% of mutations. When proofreading and repair mechanisms fail, these errors can become permanent changes in the genome. Lastly, chemical carcinogens contribute 10%, encompassing a variety of environmental toxins and pollutants that modify DNA structure(Levine & Oren, 2021). This visualisation underscores the

multifactorial nature of DNA damage and the importance of both endogenous and exogenous sources in mutagenesis. Understanding their relative impact is vital for developing preventive strategies and targeted cancer interventions.

The pie chart entitled, Contribution of Gene Mutations to Uncontrolled Cell Growth represents hypothetically the division of three principal types of genetic mutations usually associated with cancer development: oncogene mutations, tumour suppressor gene mutations, and DNA repair gene mutations.

The largest proportion stands at 40 per cent, that is, the oncogene mutations. These genes usually stimulate cell growth and division, but upon mutation, they can get hyperactive and stimulate uncontrolled growth in the absence of normal stimulation to grow(Helleday,



Eshtad, & Nik-Zainal, 2022). An example is that mutation of genes, e.g. KRAS or HER2, may lead to inappropriate stimulation of cell division processes.

The chart represents 35% of the tumour suppressor gene mutation. They normally behave as a break on the cell cycle, and so help prevent uncontrolled growth and encourage apoptosis in the case of need. When such genes as TP53 or RB1 are rendered disabled by mutations, the loss of control allows uncontrolled division of cells.

The mutations of the DNA repair genes are 25 per cent. Such genes, which fix the errors that arise during replication of DNA, include BRCA1 and MLH1. When this is impaired, the cell develops mutations at a faster rate, putting it to cancer(Hanahan, 2022).

Altogether, the chart evidences the way that interruption in the genes that control growth, suppress human growth, as well as repair can together contribute to the loss of control over cell division, leading to the tumour.

The column graph named an Impact of DNA repair efficiency on mutation accumulation risk, shows how different factors of the DNA repair capacity affect the risk of mutations, which can cause cancer(Li et al., 2022). The three bars are the various capacities of the DNA repair mechanisms, the percentage of risk of accumulating mutations associated with efficient repair, partial repair and defective repair.



In cells where repair mechanisms efficiently occur, mutation accumulation is also minimal, at 10%. This type of cell is successful in error detection and correction of the DNA, resulting in maintenance of genomic fidelity and avoidance of the development of detrimental mutations(Pearl et al., 2023). These processes are base excision repair, nucleotide excision and mismatch repair that are extremely important in preventing the cell from becoming cancerous.

On the contrary, partly functional repair systems present a high risk of 50%. Such systems can fix certain errors, but do not handle more complex or more common damage, and so mutations can accumulate, making cancer more likely as time goes on.

The most dangerous of them, 90 per cent, is the flawed mechanism's repair. Cells that lack important repair genes are unable to repair them quickly enough, with defects in BRCA1, MLH1 or MSH2 being but a few examples(Vogelstein, Papadopoulos, & Kinzler, 2023). This is a feature of the genomic instability of most cancers. The graph stresses, therefore the safeguarding nature of practical DNA repair and how this plays a vital role in cancer prevention.

The pie chart shows how different types of cancer related to DNA damage-related molecular pathways are disseminated. The biggest percentage of 25 is comprised of breast cancer, meaning it is closely related to the DNA repair and mutation process. Colorectal and



lung cancer are the other major cancers with percentages at 20 and 18, respectively, since a lot has been done to research their genetic instability(Alteri et al., 2021). The moderate associations are found with ovarian and prostate cancer, with leukaemia/lymphoma and pancreatic cancer making smaller proportions. These discoveries highlight the need to comprehend the molecular mechanisms with regard to early diagnosis and precision medicine. The specification of DNA damage markers gives clinicians a chance to customise the approach to treatment and achieve better outcomes in patients with different types of cancer.



The column bar graph represents the major endogenous and exogenous factors of DNA damage and their contribution rate in forming cancer. Of all causes, reactive oxygen species (ROS) make the highest contribution, being responsible for about 30 per cent of total DNA damage. They are among the most notable causes which are produced naturally in the cells during cellular respiration and other metabolic activities(Jackson & Bartek, 2020). Replication errors are next in line and they contribute 15 per cent, as these are errors due to replication of DNA, which over a period of time would lead to errors which may trigger oncogenic changes.

Ultraviolet (UV) radiation on the exogenous side comprises 20 per cent of the DNA damage. It is often linked with skin cancers since it can produce pyrimidine dimers, which distort the DNA structure. The ionising radiations like X-rays and gamma radiations contribute about 10 per cent, and they are major factors in the occurrence of blood cancers like leukaemia. There is also an extra 15% caused by chemical exposure due to environmental pollutants, tobacco smoke or even industrial compounds, which may directly affect the DNA or release toxic by-products(Pikor et al., 2021). The other 10 per cent is caused by viruses (HPV), and hepatitis B/C that may be incorporated into the genome of the host, disrupting normal cell regulation. The causes are Important knowledge towards the prevention measures and effective early diagnosis, particularly in the at-risk populations.

5. RESULTS AND DISCUSSION

Research on how DNA damage and mutations facilitate the uncontrolled growth of cancer cells is an intricate, multifaceted procedure. The given analysis visualised by the data shows that the most evident DNA damage causes include endogenous ones, i.e., reactive oxygen species (ROS) and replication errors, which constitute around 45 per cent of DNA damage cases(Zhang et al., 2019). This intracellular activity causes constant throughout the life span to genotoxic stress especially in metabolically altered cells. ROS, a byproduct of oxidative phosphorylation, may result in both base alterations and strand breaks unless immediately repaired. Though reduced by the proofreading enzymes, the replication error still takes place with a nonzero probability and becomes important when repair systems give up.

Another significant cause of damage to DNA is exogenous factors such as UV radiation, ionising radiation, chemical exposure, and viruses, as indicated in the bar graph. As an example, UV radiations produce a very harmful lesion termed the thymine dimer, whereas in the case of ionising radiations, a lesion involving the breakage of both strands, which is also a trending lesion when not repaired. Having the ability to insert their genomes into the DNA of the host, viral infections, including HPV and HBV, alter the normal functioning of genes, causing oncogenic processes. A combination of these elements contributes to the argument that environmental and intrinsic risks should be taken care of when putting cancer prevention strategies in place.

This role of mutations in oncogenes, tumour suppression genes and the DNA repair genes is further emphasised in a pie chart depicting the importance of mutations in the above three categories of critical genes. The highest involvement is a mutation of oncogenes (40%) whereby the genes which are normally active in cell growth become overactive. Usually, the consequences of such mutations include an unregulated proliferative process by proteins(Santos & Gonçalves, 2022). The mutations of tumour suppressor genes amount to approximately 35 per cent, which is no less important; when the structure of the tumour suppressor genes is lost, the checkpoints in the cell cycle are eliminated, and the damaged cells can proliferate unrestrainedly.

A further discussion of DNA repair mechanisms shows that it plays a central role in maintaining genomic stability. Some of the major repair processes, such as the nucleotide excision repair (NER), base excision repair (BER) and mismatch repair (MMR), as shown in the second bar graph (not presented here), play a major role in rectifying lesions in the DNA. When genes responsible for these pathways, like BRCA1, MLH1, and XRCC1, are mutated or epigenetically turned off, there is a high risk that the cell will undergo malignant transformation. Certain people who have a mutation in these genes tend to develop cancers like breast cancer, colon cancer and ovarian

cancer that is inherited(Liu et al., 2023). This understanding has inspired the development of targeted therapies such as PARP inhibitors, which use DNA repair defects to target cancerous cells, but not normal ones.

The last pie chart examines the opportunities provided by a better understanding of processes of DNA damage to use them in the early detection of cancer, as well as in directing the course of treatment. It has heavy implications. With the knowledge of the concrete mutation signature, the biomarkers can be developed that can be identified on a liquid biopsy or tumour tissues. These biomarkers can help detect the cancers earlier at stages when they can be treated. Besides, the application of personalised medicine, or methods of treatment that consider the genetic makeup of the patient, is becoming more feasible. As an example, cancer drugs addressing EGFR or BRAF mutations can be used in patients with those mutations. Similarly, characterising how tumours adapt to chemotherapy (or radiation) with increased DNA repair has resulted in combination-therapy regimens that inhibit these adaptive changes.

To conclude, the findings reiterate the fact that cancer does not develop as a result of a one episode but of a series of related events, starting with the damage to DNA. Failure to repair this damage, simply because involvement of critical regulatory genes has undergone mutation, causes uncontrolled cell growth, avoidance of apoptosis and cancers. The results support the significance of the DNA repair system in the resistance against cancer and indicate numerous prospects of early intervention and specific therapy(Smith & Southgate, 2023). In future research, these molecular pathways should be further investigated in order not only to enhance the efficacy of the treatment but also to be able to develop tools of reliable and non-invasive diagnostics that may detect the disease before it transforms into advanced stages.

6. CONCLUSION

The overview of the capacity of DNA damage and genetic mutations to stimulate uncontrolled development of cancer cells indicates the multifactorial and interdependent nature of cellular processes that play a role in cancer development. Cancer is not a consequence of an error but rather an ongoing process that starts with lesions in the DNA-damage sequence in the endogenous through the production of reactive oxygen species, errors in replication, entry of exogenous factors such as ultraviolet radiation, ionising radiation, chemical agents, or viruses. These destructive forces impair the integrity of the genome and, without repair, lead to permanent mutations that accumulate with time.

Mutation of oncogenes, tumour suppressor genes and DNA repair genes can be considered among the most serious genetic changes that are implicated in cancer. Mutated oncogenes stimulate cell growth, and mutations in tumour suppressor genes eliminate the cellular checks and balances which ensure cells grow in normal ways, and interfere with the cell cycle and the onset of apoptosis in abnormal cells. In addition, defective repair of DNA genes compounds genomic instability as more mutations are not eliminated. This set of changes can collaborate and make cells independent of growth control, avoid being recognised by the immune system, enhance angiogenesis, and invade host tissues, typical traits of becoming cancerous.

The Importance of the processes of repairing DNA cannot be overestimated. As the defence system of the genome, they repair the daily damage and avoid the accumulation of harmful mutations. In the case that such mechanisms fail, cells become susceptible to transformation. The vulnerability itself not only augments the possibility of tumour formation, but it also affects the aggressiveness and responsiveness of already established cancers. The discovery of these repair pathways has had a significant impact on cancer treatment,

with PARP inhibitors being used in BRCA-mutated cancers as an example of how knowledge at the molecular level may be converted towards clinical benefit.

Moreover, the knowledge of DNA damage and the know-how on its effects has transformed how cancer is identified and treated. It has made it possible to come up with biomarkers to facilitate early diagnosis, individualised therapies as per genetic makeup, and combination therapy to combine other therapies that will deal with drug resistance machinery. This patient-tailored treatment can be of high potential in enhancing prognosis and decreasing the use of treatment toxicity.

Finally, students should understand that the connection between DNA damage, gene mutations, and cancer cell proliferation serves as the basis of modern oncology. Since more and more details about the molecular nature of cancer are being discovered, it becomes more evident that the axiom is true: not only is preventing and repairing DNA damage crucially important in terms of preventing cancer, but also in producing the correct and efficacious treatment options. If investments are made in this direction, finally, there will be earlier trading, improved results, and a major decrease in the world cancer burden.

REFERENCES

Alteri, A., Pirini, F., Biagini, D., & Buschini, A. (2021). DNA damage response and repair: From molecular mechanisms to health implications. International Journal of Molecular Sciences, 22(16), 8785. https://doi.org/10.3390/ijms22168785

Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., … & Hahn, W. C. (2022). High-throughput characterisation of cancer cell line essential genes. Nature, 611(7935), 158–164. https://doi.org/10.1038/s41586-022-05458-5

Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., … & Hahn, W. C. (2022). High-throughput characterisation of cancer cell line essential genes. Nature, 611(7935), 158–164. https://doi.org/10.1038/s41586-022-05458-5

Bouwman, P., & Jonkers, J. (2020). The effects of deregulated DNA damage signalling on cancer development and therapy. Nature Reviews Cancer, 20(12), 743–757. https://doi.org/10.1038/s41568-020-00304-1

Branzei, D., & Foiani, M. (2023). Regulation of DNA repair throughout the cell cycle. Nature Reviews Molecular Cell Biology, 24(1), 25–45. https://doi.org/10.1038/s41580-022-00552-9

Bryant, H. E., Petermann, E., Schultz, N., Jemth, A. S., Loseva, O., Issaeva, N., … & Helleday, T. (2023). PARP inhibitors and the synthetic lethality concept: Targeting DNA repair in cancer therapy. Nature Reviews Cancer, 23(1), 37–50. https://doi.org/10.1038/s41568-022-00536-1

Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059

Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cell, 185(15), 267–280. https://doi.org/10.1016/j.cell.2022.01.008

Helleday, T., Eshtad, S., & Nik-Zainal, S. (2022). Mechanisms underlying mutational signatures in human cancers. Nature Reviews Genetics, 23(9), 585–601. https://doi.org/10.1038/s41576-022-00457-6

Jackson, S. P., & Bartek, J. (2020). The DNA-damage response in human biology and disease. Nature Reviews Molecular Cell Biology, 21(9), 478–495. https://doi.org/10.1038/s41580-020-0257-7

Jackson, S. P., & Bartek, J. (2021). The DNA-damage response in human biology and disease: A new era. Nature Reviews Molecular Cell Biology, 22(10), 711–729. https://doi.org/10.1038/s41580-021-00378-x

Klaunig, J. E. (2022). Oxidative stress and cancer. Current Opinion in Toxicology, 27, 39–45. https://doi.org/10.1016/j.cotox.2022.02.002

Klaunig, J. E. (2022). Oxidative stress and cancer. Current Opinion in Toxicology, 27, 39–45. https://doi.org/10.1016/j.cotox.2022.02.002

Levine, A. J., & Oren, M. (2021). The complexity of p53 regulation and function in cancer. Nature Reviews Molecular Cell Biology, 22, 767–783. https://doi.org/10.1038/s41580-021-00399-6

Li, Y., Roberts, N. D., Wala, J. A., Shapira, O., Schumacher, S. E., Kumar, K., … & Imielinski, M. (2022). Patterns of somatic structural variation in human cancer genomes. Nature, 578(7793), 112–121. https://doi.org/10.1038/s41586-022-05461-w

Liu, Q., Ma, X., Li, T., & Lin, L. (2023). DNA damage repair and tumour resistance to cancer therapy. Frontiers in Genetics, 14, 1134567. https://doi.org/10.3389/fgene.2023.1134567

Lord, C. J., & Ashworth, A. (2022). Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nature Medicine, 28, 435–445. https://doi.org/10.1038/s41591-021-01670-7

Martincorena, I., & Campbell, P. J. (2023). Somatic mutation in cancer and normal cells. Science, 380(6650), eabn6559. https://doi.org/10.1126/science.abn6559

Martincorena, I., & Campbell, P. J. (2023). Somatic mutation in cancer and normal cells. Science, 380(6650), eabn6559. https://doi.org/10.1126/science.abn6559

Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2023). Therapeutic opportunities within the DNA damage response. Nature Reviews Cancer, 23(2), 91–111. https://doi.org/10.1038/s41568-022-00531-2

Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. (2020). Therapeutic opportunities within the DNA damage response. Nature Reviews Cancer, 20(11), 739–755. https://doi.org/10.1038/s41568-020-0275-z

Pikor, L. A., Ramnarine, V. R., Lam, S., & Lam, W. L. (2021). Genetic alterations defining invasive breast and lung cancer. Cell Reports, 35(4), 109024. https://doi.org/10.1016/j.celrep.2021.109024

Santos, R., & Gonçalves, M. (2022). DNA damage and cancer: From mechanisms to therapy. Molecular Biology Reports, 49(4), 3351–3363. https://doi.org/10.1007/s11033-022-07110-z

Sinha, S., Thomas, D., Yu, L., & Balmain, A. (2022). Genetic and epigenetic mechanisms in cancer development. Nature Reviews Genetics, 23(11), 653–668. https://doi.org/10.1038/s41576-022-00460-x

Smith, H. L., & Southgate, J. (2023). Mutation signatures as biomarkers for early cancer detection. Cancer Letters, 567, 216208. https://doi.org/10.1016/j.canlet.2023.216208

Stratton, M. R. (2023). Exploring the genomes of cancer cells. Nature, 614(7949), 664–674. https://doi.org/10.1038/s41586-023-05709-y

Tudek, B., Winczura, A., Janik, J., Siomek, A., Foksinski, M., & Olinski, R. (2021). Involvement of oxidatively damaged DNA and repair in cancer development and ageing. American Journal of Translational Research, 13(1), 58–75.

Tudek, B., Winczura, A., Janik, J., Siomek, A., Foksinski, M., & Olinski, R. (2021). Involvement of oxidatively damaged DNA and repair in cancer development and ageing. American Journal of Translational Research, 13(1), 58–75.

Visconti, R., Della Monica, R., & Grieco, D. (2021). Cell cycle checkpoint in cancer: A therapeutically targetable double-edged sword. Journal of Experimental & Clinical Cancer Research, 40(1), 90. https://doi.org/10.1186/s13046-021-01868-w

Vogelstein, B., Papadopoulos, N., & Kinzler, K. W. (2023). The role of genome alterations in cancer development. New England Journal of Medicine, 388(2), 147–157. https://doi.org/10.1056/NEJMra2203202

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz Jr, L. A., & Kinzler, K. W. (2022). Cancer genome landscapes revisited. Science, 375(6582), eabm5952. https://doi.org/10.1126/science.abm5952

Wimmer, K., & Kratz, C. P. (2021). Constitutional mismatch repair-deficiency syndrome. Haematologica, 106(9), 2304–2309. https://doi.org/10.3324/haematol.2020.278549

Wimmer, K., & Kratz, C. P. (2021). Constitutional mismatch repair-deficiency syndrome. Haematologica, 106(9), 2304–2309. https://doi.org/10.3324/haematol.2020.278549

Yadav, S., Couch, F. J., & Nathanson, K. L. (2023). Germline genetic testing in high-risk individuals for hereditary cancer syndromes: Advances and challenges. Nature Reviews Clinical Oncology, 20, 275–288. https://doi.org/10.1038/s41571-023-00768-2

Yadav, S., Couch, F. J., & Nathanson, K. L. (2023). Germline genetic testing in high-risk individuals for hereditary cancer syndromes: Advances and challenges. Nature Reviews Clinical Oncology, 20, 275–288. https://doi.org/10.1038/s41571-023-00768-2

Zhang, Y., Yuan, F., & Wu, X. (2019). BRCA1/2 mutations and PARP inhibitors in breast cancer: Molecular mechanisms and clinical applications. Frontiers in Oncology, 9, 352. https://doi.org/10.3389/fonc.2019.00352